Can GSK’s Hepatitis B Breakthrough Become a £2 Billion Opportunity?

GSK plc (NYSE:GSK) has reached two important regulatory milestones involving treatments for chronic hepatitis B and rectal cancer. Bepirovirsen, which is now branded as Hibsago, was approved by Japan, marking the drug’s first authorization anywhere in the world. In a separate development, the FDA granted priority review to an application seeking approval of GSK’s (NYSE:GSK) cancer therapy Jemperli for locally advanced rectal cancer.

The two developments strengthen different parts of GSK’s pipeline. Hibsago has secured its first regulatory approval, while Jemperli remains under FDA review for the proposed rectal-cancer indication.

Bull Case

The approval of Hibsago represents the more immediate milestone for the company, as GSK described it as the first and only treatment approved in Japan to deliver a functional cure for chronic hepatitis B. The approval was supported by late-stage studies in which nearly one in five patients achieved a functional cure. Although that result applied to a minority of participants, it offers the possibility of a finite treatment course for some patients instead of continued reliance on lifelong antiviral pills.

Hibsago is designed to address chronic hepatitis B through three mechanisms. It blocks replication of viral DNA, reduces levels of hepatitis B surface antigen in the blood, and strengthens the immune response to support longer-lasting control of the disease. That multi-part approach underpins GSK’s attempt to move treatment beyond continuous viral suppression. The commercial expectations are also substantial. GSK has forecast that bepirovirsen could generate more than £2 billion, or approximately $2.73 billion, in peak annual sales, and if the drug approaches that target, it could contribute meaningfully to the company’s goal of producing more than £40 billion in annual revenue by 2031.

In addition, the Jemperli development broadens the positive regulatory picture. The FDA has accepted the therapy for priority review as a possible treatment for locally advanced rectal cancer, and while a priority review shortens the agency’s review timetable, it does not indicate that approval is assured. The FDA assigned an action date in February 2027, and GSK said the structure of the program could potentially allow a decision before that deadline.

Jemperli had previously received both Breakthrough Therapy and Fast Track designations for the proposed use, demonstrating the regulator’s willingness to facilitate its development and review. An approval would add locally advanced rectal cancer to Jemperli’s existing authorizations in specific subtypes of endometrial cancer, expanding the medicine’s potential patient population.

Bear Case

Hibsago’s late-stage results also reveal the treatment’s principal limitation, which is that nearly one in five patients achieved a functional cure, meaning most study participants did not reach that outcome. Investors will need to see whether the clinical results translate into meaningful prescribing demand following launch.

It is also significant to note that Japan is currently Hibsago’s only approved market. Its first global authorization validates an important part of the program, but it does not guarantee approval or commercial success in other countries. GSK’s projection of more than £2 billion in peak annual sales remains a company forecast rather than established revenue.

The Jemperli development is earlier in the regulatory process, and while the priority review accelerates consideration of the application, it is not an approval. Jemperli is not currently approved anywhere for locally advanced rectal cancer, and priority review does not guarantee that the FDA will approve the application. The possible earlier decision should also be treated cautiously. February 2027 is the formal FDA action date, while any decision before then remains a possibility rather than a confirmed timeline.

Conclusion

Hibsago’s first approval gives GSK a regulatory entry into functional-cure treatment for chronic hepatitis B in Japan, while Jemperli’s priority review creates an opportunity to expand the cancer therapy into rectal cancer. Together, the developments provide tangible evidence of pipeline progress.

The investment implications now depend on execution. GSK must translate Hibsago’s Japanese approval into adoption and pursue access in additional markets, while Jemperli must still complete the FDA review process. These are meaningful regulatory advances, but their eventual value will be determined by factors such as approvals, demand, and commercial performance.

READ NEXT: Can Eli Lilly Catch Novo Nordisk in the Oral GLP-1 Race? AND Abbott vs. Intuitive Surgical: Is Consistent Growth Better Than Premium Growth? 

This article is originally published at Insider Monkey.